{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-005203","form_type":"8-K","ticker":"BCPC","cik":"0000009326","company_name":"BALCHEM CORP","filed_at":"2024-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.341913+00:00","generated_at":"2026-06-06T00:35:52.126172+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Balchem Q4 adj. EBITDA up 5.4% to $55.4M; free cash flow $56M, record Human Nutrition sales","bullets":["Q4 GAAP EPS $0.82 vs $0.66 prior year; adjusted EPS $0.95 vs $0.94.","Full year adjusted EBITDA $230.9M (+7.1%); record free cash flow $151.1M.","Human Nutrition & Health Q4 sales $138M (+5.8%) record; earnings from ops up 43.8%.","Dividend increased double-digit; $25.4M returned to shareholders in 2023.","CEO expects both top and bottom line growth for full year 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-005203","json":"https://secwatch.observer/filing/0001628280-24-005203.json","markdown":"https://secwatch.observer/filing/0001628280-24-005203.md","text":"https://secwatch.observer/filing/0001628280-24-005203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/9326/000162828024005203/0001628280-24-005203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/9326/000162828024005203/bcpc-20240216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:35:52.126172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a70e28f1ca237b4de4fb40192778293eee96ffa7","claim":"BALCHEM CORP reported Q4 2023 (three months ended December 31, 2023) results: revenue $228.7 million, net income $26.6 million, EPS $0.82.","evidence_excerpt":"The Company reported quarterly net sales of $228.7 million, quarterly net earnings of $26.6 million, adjusted EBITDA (a) of $55.4 million, and free cash flow (a) of $56.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/9326/000162828024005203/0001628280-24-005203-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 2023 (three months ended December 31, 2023)"},{"label":"Revenue","value":"$228.7 million"},{"label":"Net income","value":"$26.6 million"},{"label":"EPS","value":"$0.82"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b717ecb809ee2a5a4925468430bea1e3db1382f8","claim":"BALCHEM CORP reported FY 2023 (year ended December 31, 2023) results: revenue $922.4 million, net income $108.5 million, EPS $3.35.","evidence_excerpt":"Full Year 2023 Financial Highlights: • GAAP net earnings were $108.5 million, an increase of 3.0% from the prior year. These net earnings resulted in GAAP earnings per share of $3.35 compared to $3.25 in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/9326/000162828024005203/0001628280-24-005203-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY 2023 (year ended December 31, 2023)"},{"label":"Revenue","value":"$922.4 million"},{"label":"Net income","value":"$108.5 million"},{"label":"EPS","value":"$3.35"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}